Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

Autor: Yi Lu, Zhongjian Chen, Wei Wu, Pijush Kumar Paul, Quangang Zhu, Jianping Qi
Rok vydání: 2021
Předmět:
CPP
cell penetrating peptide

RGD
Arg-Gly-Asp

FA - Folic acid
DDVAP
desmopressin acetate

GRAS
generally recognized as safe

PLA
poly(latic acid)

EPR
electron paramagnetic resonance

pI
isoelectric point

PLGA
poly(lactic-co-glycolic acid)

MSNs
mesoporous silica nanoparticles

Review
FcRn
Fc receptor

GIPET
gastrointestinal permeation enhancement technology

SGC
sodium glycocholate

Bioinformatics
FA
folic acid

EDTA
ethylene diamine tetraacetic acid

0302 clinical medicine
Medicine
MCT-1
monocarborxylate transporter 1

General Pharmacology
Toxicology and Pharmaceutics

health care economics and organizations
PBPK
physiologically based pharmacokinetics

STC
sodium taurocholate

0303 health sciences
IBD
inflammatory bowel disease

pHPMA
N-(2-hydroxypropyl)methacrylamide

PVA
poly vinyl alcohol

Enzyme inhibitor
HPMCP
hydroxypropyl methylcellulose phthalate

CaP
calcium phosphate

GI
gastrointestinal

PGA
poly-γ-glutamic acid

Oral delivery
HBsAg
hepatitis B surface antigen

TMC
N-trimethyl chitosan

Permeation enhancer
LBNs
lipid-based nanoparticles

030220 oncology & carcinogenesis
SNEDDS
self-nanoemulsifying drug delivery systems

Parenteral route
SDC
sodium deoxycholate

DCs
dendritic cells

SIF
simulated intestinal fluids

NLCs
nanostructured lipid carriers

Stability
VB12
vitamin B12

WGA
wheat germ agglutinin

education
High selectivity
RM1-950
EPD
empirical phase diagrams

Clinical
03 medical and health sciences
PPs
proteins and peptides

TfR
transferrin receptors

CAGR
compound annual growth

LMWP
low molecular weight protamine

SAR
structure–activity relationship

Tf
transferrin

IBD - Inflammatory bowel disease
sCT
salmon calcitonin

sc
subcutaneous

GLP-1
glucagon-like peptide 1

Tf transferrin
030304 developmental biology
PCL
polycarprolacton

PCA
principal component analysis

ILs
ionic liquids

business.industry
Proteins
NAC
N-acetyl-l-cysteine

UEA1
ulex europaeus agglutinin 1

SLNs
solid lipid nanoparticles

PAA
polyacrylic acid

SGF
simulated gastric fluids

DTPA
diethylene triamine pentaacetic acid

GALT
gut-associated lymphoid tissue

CD - Crohn's disease
Clinical trial
FDA
U.S. Food and Drug Administration

UC
ulcerative colitis

SNAC
sodium N-[8-(2-hydroxybenzoyl)amino]caprylate

COPD
chronic obstructive pulmonary disease

RTILs
room temperature ionic liquids

TAT
trans-activating transcriptional peptide

UC - Ulcerative colitis
BSA
bovine serum albumin

CD
Crohn's disease

Therapeutics. Pharmacology
ASBT
apical sodium-dependent bile acid transporter

Peptides
business
Zdroj: Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica B, Vol 11, Iss 8, Pp 2416-2448 (2021)
ISSN: 2211-3835
DOI: 10.1016/j.apsb.2021.04.001
Popis: Proteins and peptides (PPs) have gradually become more attractive therapeutic molecules than small molecular drugs due to their high selectivity and efficacy, but fewer side effects. Owing to the poor stability and limited permeability through gastrointestinal (GI) tract and epithelia, the therapeutic PPs are usually administered by parenteral route. Given the big demand for oral administration in clinical use, a variety of researches focused on developing new technologies to overcome GI barriers of PPs, such as enteric coating, enzyme inhibitors, permeation enhancers, nanoparticles, as well as intestinal microdevices. Some new technologies have been developed under clinical trials and even on the market. This review summarizes the history, the physiological barriers and the overcoming approaches, current clinical and preclinical technologies, and future prospects of oral delivery of PPs.
Graphical abstract The current strategies for improving oral absorption of proteins and peptides (PPs) include stabilization, absorption enhancement and mucus-related technologies. Most of marketed oral PP products employ two or more strategies.Image 1
Databáze: OpenAIRE